Study of FCN-437c in Patients With Advanced Solid Tumors

NCT03951116 | Completed Phase 1 FDA Drug

• 1 other identifier: FCN-437c-001
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 3

Brief Summary

This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.

Conditions

Solid Tumor, Adult

Keywords

solid tumor

Outcome Measures

Primary Outcomes (3)

• To quantify the occurrence of adverse events (AEs) reported in all subjects who received study drug

  Incidence of untoward medical occurrences (adverse event = AE) in a participant who received study drug. Adverse events will be evaluated by dosing cohort and recorded according to NCI CTCAEv5 Common Toxicity Criteria.

  From enrollment up to 30 days after last dose

• To determine the occurrence of treatment-emergent adverse events (TEAs)

  Incidence of untoward medical occurrences (adverse event = AE) attributed to study drug in a participant who received study drug. Adverse events will be evaluated and recorded by dosing cohort according to NCI CTCAEv5 Common Toxicity Criteria.

  From first dose up to 30 days after last dose

• To determine the occurrence of treatment-related adverse events meeting the criteria for dose limiting toxicities (DLTs)

  Incidence of the DLT population will consist all subjects who received the required amount of study drug during the DLT observation period of 28 days (21 days of daily dosing, 7 days of no dosing) of study treatment . Treatment-related AE is any untoward medical occurrence attributed to study drug in a participant that who received study drug. Treatment-related AE is any untoward medical occurrence attributed to study drug in a participant who received study drug. DLTs are adverse events meeting the protocol-specified criteria, evaluated and recorded according to NCI CTCAEv5 Common Toxicity Criteria will use medical terminology based on the Medical Dictionary for Regulatory Activities Terminology (MedDRA).

  From first dose up to 28 days

Secondary Outcomes (9)

• To quantify the area under the serum concentration versus time curve (AUC) of FCN-437c after administration as a single agent

  2 months

• To quantify the last time point with a quantifiable concentration (AUClast) of FCN-437c after administration as a single agent

  2 months

• To quantify the plasma concentrations at the end of a dosing interval (Ctau) of FCN-437c after administration as a single agent

  2 months

• To quantify the lowest plasma concentration at the end of a dosing interval (Ctrough)

  2 months

• To measure the time to reach the highest plasma concentrations (Tmax) of FCN-437c after single agent administration

  2 months

Other Outcomes (4)

• To correlate the degree of tumor-specific CDK4/6 inhibition to the dose level of FCN-437c

  Baseline up to approximately 1 year

• To correlate the degree of dose-related tumor-specific CDK4/6 inhibition of FCN-437c and tumor response

  Baseline up to approximately 1 year

• To correlate the retinoblastoma (Rb) protein expression as a potential predictive biomarker to FCN-437c tumor response according to RECIST 1.1 criteria

  Baseline up to approximately 1 year

Study Arms (1)

Dose escalation cohort of FCN-437c

EXPERIMENTAL

The dose-escalation cohort: * Participants will receive FCN-437c monotherapy once daily (QD) for 21 days followed by a 7 day rest period (28-day cycle). * FCN-437c will be administered orally. * Participants with histologically or cytologically confirmed advanced unresectable/metastatic solid tumor will participate in this cohort.

Drug: FCN-437

Interventions

FCN-437 DRUG

FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.

Dose escalation cohort of FCN-437c

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have given written informed consent prior to any study specific procedures
• Male or female subject ≥ 18 years
• Histologically/cytologically confirmed, unresectable locally advanced or metastatic solid tumors that are refractory to standard therapy or for which no standard therapy exists. Note for patients with non-small cell lung cancer \[NSCLC\] and patients with activating ALK translocation, or EFGR mutations must have been treated and failed appropriate targeted treatment).
• Subjects enrolled in cohort expansion at MTD should have specific tumor types as below:
• KRAS mutant NSCLC confirmed by a documented historical report
• Breast cancer previously treated with a CDK4/6 inhibitor
• All subjects should have evaluable disease as per RECIST 1.1 (Eisenhauer, 2009).
• Subjects enrolled in cohort expansion at MTD should have measurable disease (presence of at least one measurable lesion) as per RECIST 1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1
• Subjects with life expectancy of ≥ 3 months
• Subjects with central nervous system (CNS) metatases are eligible if clinically controlled that is defined as surgical excision/and or radiation therapy followed by 3 weeks of stable neurologic function and no evidence of CNS disease progression as determined by contrast-enhanced computer tomography (CT) and nuclear magnetic resonance imaging (MRI) within 3 weeks prior to the first dose of study drug.
• Must have adequate organ function, including the following:
• Bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.5 X 10 9/L; platelet count ≥ 100 x 10 9/L;hemoglobin ≥ 9g/dL or ≥ 5.6 mmol/L
• Hepatic: total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate transaminase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 times ULN (\< 5 times ULN if liver metastases).
• Renal: estimated creatinine clearance ≥ 45 mL/min based on the Cockcroft-Gault equation (Appendix 19.4).

You may not qualify if:

• Females during pregnancy or breastfeeding.
• Subjects on any anticancer therapy approved or experimental, including chemotherapy, immune therapy, radiation therapy, hormonal therapy (Exceptions: hormone-replacement therapy, testosterone or oral contraceptives), biologic therapy, within 3 weeks (or 5 half-lives whichever is shorter) prior to initiation of study treatment. Note: Subjects should be recovered from treatment related toxicity resolved to baseline except for residual alopecia.
• Subjects who had prior treatment with a CDK4/6 inhibitor except Hormone receptor (HR)+/Human epidermal growth factor receptor 2 (HER2)- breast cancer patients who may have received CDK4/6 inhibitor as a standard treatment.
• Subjects with history of gastric bypass surgery or banding procedure.
• Subjects who have had major surgery within the 28-days from the screening or subjects who have undergone organ transplant surgery.
• Active hepatitis B (HBV) or hepatitis C (HCV). HBV carriers without active disease (HBV DNA titer \< 1000 cps/mL or 200 IU/mL), or cured HCV (negative HCV RNA test) may be enrolled. Subjects with controlled human immunodeficiency virus (HIV) disease may be eligible.
• Subjects with a concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor.
• Unresolved toxicities (other than alopecia) from previous anti-cancer therapy defined as toxicities not resolved to NCI CTCAE Version 5.0, Grade ≤ 1.
• Subject who have had severe infection within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose administration.
• Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure New York Heart Association (NYHA) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 3 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
• A resting ECG with QTcF ≥ 470 msc or the subject has a congenital prolonged QT syndrome or with concomitant medications known to prolong the QT interval.
• Taking a prohibited concomitant medication or inability to follow concomitant medications guidelines
• Any other serious underlying medical (e.g., uncontrolled diabetes mellitus, uncontrolled hypertension, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, severe hearing impairment, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, cardiac conditions), psychiatric, psychological, familial or geographical condition that, in the judgment of the Investigator, may interfere with the planned staging, treatment and follow-up, affect subject compliance or place the subject at high risk from treatment-related complications.

Sponsors & Collaborators

• Fochon Pharmaceuticals, Ltd.: lead

Study Sites (3)

City of Hope National Medical Center

Duarte, California, 91010, United States

Location

Sarah Cannon Research Institute at Tennessee Oncology

Nashville, Tennessee, 37203, United States

Location

South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, 78229, United States

Location

MeSH Terms

Interventions

FCN-437c

Study Officials

• Amita Patmaik, MD

  South Texas Accelerated Research Therapeutics

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Open-Label Phase 1 Dose escalation study

Study Record Dates

• First Submitted: May 9, 2019
• First Posted: May 15, 2019
• Study Start: June 25, 2019
• Primary Completion: December 8, 2021
• Study Completion: December 8, 2021
• Last Updated: March 16, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)